




Highly Adaptable AdenoVerse™ Technology Platform for Therapeutics and Vaccines

Licensing Opportunity

- Well-established, agile and flexible turnkey solution to deliver genes
- Novel, proprietary adenovectors based on multiple serotypes for therapeutics and vaccines
- Licensing packages include key intellectual property covering:
 - ✓ Vector design and modification
 - ✓ Access to GenVec's proprietary industrial technology and manufacturing cell line(s) on a non-exclusive basis
 - ✓ Cross-reference to FDA Master file and access to Master Cell Bank(s)



Highlights

- GenVec's proprietary multiply-deleted vectors:
 - ✓ Ensure replication block
 - ✓ Provides large payload capacity capable of delivering multiple genes in a single construct
 - ✓ Demonstrate high-yield productivity
- GenVec's highly potent adenovectors include rare human and non-human low-seroprevalence serotypes designed to provide superior performance characteristics for a variety of applications
- GenVec's GC adenovectors, built on gorilla adenovirus, have desirable characteristics for genetic vaccines
 - ✓ GC adenovectors demonstrate superior CD8+ T cell responses in preclinical studies
 - ✓ Repeat administration of GC adenovectors increases T cell responses in preclinical studies

Description

GenVec, a leader in adenovector technology, has built and tested adenovectors from a broad array of human and non-human serotypes. GenVec's expertise allows for the design and customization of vectors to address specific disease issues, whether for therapeutics or vaccines.

About GenVec

GenVec is a clinical-stage biopharmaceutical company with an entrepreneurial focus on leveraging its proprietary AdenoVerse™ gene delivery platform to develop a pipeline of cutting-edge therapeutics and vaccines. The company is a pioneer in the design, testing and manufacture of adenoviral-based product candidates that can deliver on the promise of gene-based medicine. Current GenVec partners and collaborators include leading organizations such as Novartis and the U.S. Government.

For further information, please contact:

Sebastien Maloveste, Ph.D.
Assoc. Dir., Business Development
Tel: 240-801-8602
smaloveste@genvec.com

Adrian Riddell
Assoc. Dir., Business Development
Tel: 240-801-8600
ariddell@genvec.com

